XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Note 1 - Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Notes Tables |
Debt Securities, Available-for-sale [Table Text Block] |
|  | June 30, 2018
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of the U.S. Government and its agencies |  | $ | 47,023 |  |  | $ | 136 |  |  | $ | — |  |  | $ | (204 | ) |  | $ | 46,955 |
Corporate debt securities |  |  | 33,465 |  |  |  | 199 |  |  |  | — |  |  |  | (226 | ) |  |  | 33,438 |
Certificates of deposit |  |  | 6,985 |  |  |  | 24 |  |  |  | — |  |  |  | (22 | ) |  |  | 6,987 |
Total investments |  | $ | 87,473 |  |  | $ | 359 |  |  | $ | — |  |  | $ | (452 | ) |  | $ | 87,380 |
|  | December 31, 2017
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of the U.S. Government and its agencies |  | $ | 60,121 |  |  | $ | 177 |  |  | $ | — |  |  | $ | (122 | ) |  | $ | 60,176 |
Corporate debt securities |  |  | 34,021 |  |  |  | 203 |  |  |  | — |  |  |  | (108 | ) |  |  | 34,116 |
Certificates of deposit |  |  | 11,099 |  |  |  | 32 |  |  |  | 1 |  |  |  | (14 | ) |  |  | 11,118 |
Total investments |  | $ | 105,241 |  |  | $ | 412 |  |  | $ | 1 |  |  | $ | (244 | ) |  | $ | 105,410 |
Available For Sale Securities Debt Maturities Fair Value [Table Text Block] |
|  | 2018 |  | 2017
Maturing in one year or less |  | $ | 53,636 |  |  | $ | 64,115 |
Maturing after one year through two years |  |  | 33,744 |  |  |  | 34,257 |
Maturing after two years |  |  | — |  |  |  | 7,038 |
Total investments |  | $ | 87,380 |  |  | $ | 105,410 |
Schedule of Receivables from Collaborations [Table Text Block] |
|  | June 30, 2018
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | 87 |  |  | $ | 1,090 |  |  | $ | 1,177 |
Shionogi & Co. Ltd. |  |  | 27 |  |  |  | — |  |  |  | 27 |
Green Cross Corporation |  |  | 51 |  |  |  | 27 |  |  |  | 78 |
Mundipharma International Holdings Limited |  |  | 43 |  |  |  | — |  |  |  | 43 |
Seqirus UK Limited |  |  | 1,017 |  |  |  | — |  |  |  | 1,017 |
Total receivables |  | $ | 1,225 |  |  | $ | 1,117 |  |  | $ | 2,342 |
|  | December 31, 2017
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | 42 |  |  | $ | 2,020 |  |  | $ | 2,062 |
Shionogi & Co. Ltd. |  |  | 1,600 |  |  |  | — |  |  |  | 1,600 |
Green Cross Corporation |  |  | 1,388 |  |  |  | 28 |  |  |  | 1,416 |
Mundipharma International Holdings Limited |  |  | 47 |  |  |  | — |  |  |  | 47 |
Seqirus UK Limited |  |  | 825 |  |  |  | 167 |  |  |  | 992 |
Total receivables |  | $ | 3,902 |  |  | $ | 2,215 |  |  | $ | 6,117 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] |
|  | Balance at December 31, 2017 |  | Adjustments due to ASC 606 |  | Balance at January 1, 2018
Assets |  |  |  |  |  |  |  |  |  |  |  |
Deferred collaboration expense |  | $ | 210 |  |  | $ | (58 | ) |  | $ | 152 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 8,484 |  |  | $ | (1,184 | ) |  | $ | 7,300 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (631,843 | ) |  | $ | 1,126 |  |  | $ | (630,717 | )
|  | June 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Assets |  |  |  |  |  |
Deferred collaboration expense |  | $ | 12 |  |  | $ | 29 |  |  | $ | 41 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 300 |  |  | $ | 592 |  |  | $ | 892 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (674,940 | ) |  | $ | 563 |  |  | $ | (674,377 | )
|  | For the Three Months Ended June 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Collaborative and other research and development revenue |  | $ | 12,352 |  |  | $ | 296 |  |  | $ | 12,648 |
Research and development expenses |  |  | 21,010 |  |  |  | 14 |  |  |  | 21,024 |
Net loss |  |  | (18,446 | ) |  |  | 282 |  |  |  | (18,164 | )
Basic and diluted net loss per share |  | $ | (0.19 | ) |  | $ | 0.01 |  |  | $ | (0.18 | )
|  | For the Six Months Ended June 30, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Collaborative and other research and development revenue |  | $ | 12,667 |  |  | $ | 592 |  |  | $ | 13,259 |
Research and development expenses |  |  | 39,451 |  |  |  | 29 |  |  |  | 39,480 |
Net loss |  |  | (44,223 | ) |  |  | 563 |  |  |  | (43,660 | )
Basic and diluted net loss per share |  | $ | (0.45 | ) |  | $ | 0.01 |  |  | $ | (0.44 | )
Disaggregation of Revenue [Table Text Block] |
|  | Three Months |  | Six Months
|  | 2018 |  | 2017 |  | 2018 |  | 2017
Royalty revenue |  | $ | 142 |  |  | $ | 489 |  |  | $ | 3,803 |  |  | $ | 6,810 |
Collaborative and other research and development revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Department of Health and Human Services |  |  | 352 |  |  |  | 2,161 |  |  |  | 667 |  |  |  | 2,815 |
Shionogi & Co. Ltd. |  |  | — |  |  |  | 296 |  |  |  | — |  |  |  | 592 |
Seqirus UK Limited |  |  | 12,000 |  |  |  | 153 |  |  |  | 12,000 |  |  |  | 2,319 |
Total collaborative and other research and development revenues |  |  | 12,352 |  |  |  | 2,610 |  |  |  | 12,667 |  |  |  | 5,726 |
Total revenues |  | $ | 12,494 |  |  | $ | 3,099 |  |  | $ | 16,470 |  |  | $ | 12,536 |

X
- Definition Tabular disclosure of available for sale securities debt maturities fair value. + References No definition available. + Details
Name: | bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure representing receivables from collaborations. + References No definition available. + Details
Name: | bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 + Details
Name: | us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration